 CAMBRIDGE, Mass. and NEW YORK, Feb. 16, 2021 GLOBE NEWSWIRE -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic off-the-shelf gene-edited Natural Killer NK and Chimeric Antigen Receptor CAR-NK cells derived from induced pluripotent stem cells iPSCs, and Cellectis Euronext Growth: ALCLS - Nasdaq: CLLS a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells UCART, announced today that they have entered into a strategic research and development collaboration to develop TALEN gene-edited iPSC NK and CAR-NK cells. 